copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Kymera AAD 2024 STAT6 KT-621 Presentation - Kymera Therapeutics KT-621 is a pM STAT6 degrader with exquisite selectivity developed with the targeted protein degradation platform at Kymera STAT6 degradation by KT-621 fully blocks IL-4 13 in key human TH2 cellular assays with picomolar IC50s lower than dupilumab
KT-621|CAS|DC Chemicals It demonstrates potent anti-glioblastoma activity by: (1) blocking tumor invasion and cytokinesis (inducing polyploidy), (2) disrupting mitochondrial dynamics to elevate ROS and trigger ferroptosis, and (3) sensitizing tumors to radiotherapy kinase inhibitors via ROS-driven PDGFR mTOR pathway activation
Kymera Therapeutics Announces Positive First-in-Human KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4 IL-13 signaling and the central driver of Th2
STAT6 Degradation: A Paradigm Shift in Immunology KT-621, with DC 50 ’s in the double-digit picomolar range, is one of the most potent degraders we have profiled at Kymera and more importantly, it retained the same degradation profile across all relevant human cell types with absolute selectivity